OBJECTIVE: To determine the extent of variation in the gene for peroxisome proliferator activated receptor g (PPARg) in patients with morbid obesity. SUBJECTS: Two hundred morbidly obese patients who underwent gastric banding surgery and 192 healthy blood donors. Diabetics were excluded. EXPERIMENTAL: The frequency of the P115Q and P12A variants in the PPARg gene was determined. Single strand conformational polymorphism (SSCP) analysis was performed on all exons, exonaintron boundaries and part of the promoter of the PPARg gene on a sub-group of 67 morbid obese patients. RESULTS: None of the morbid patients or the blood donors were carriers of the P115Q mutation. The frequency of the P12A polymorphism did not differ signi®cantly between morbid obese patients and controls and there was no statistically signi®cant association between P12A and BMI. Male blood donors who were A12A homozygotes had statistically signi®cant higher serum leptin concentrations (P 0.001). Mutation screening revealed that one patient had a T ?G transversion at 7 208 in the promoter of PPARg-2, two had silent mutations, one a T?C transition in the third base of codon 144 and the other a C?T transition in codon 297. The fourth patient had a CGC?TGC transition in codon 316 resulting in the replacement of an arginine with a cysteine. This mutation was not found in any other morbidly obese patient. CONCLUSION: Variation in the PPARg gene is unlikely to play a major role in the development of morbid obesity.
Introduction
The risk of becoming obese has a strong genetic component. 1 Since single gene defects such as those in the leptin gene are very rare, 2 it is likely that a combination of polymorphisms in one or more candidate genes may contribute to the development of obesity. Peroxisome proliferator activated receptor g (PPARg) is a member of the PPAR subfamily of the nuclear hormone receptor superfamily of ligand-activated transcription factors (for reviews see Refs 3 and 4) . It plays an important role in the differentiation of adipocytes, ectopic expression and activation of PPARg in a ®broblast cell line resulting in their differentiation into adipocytes. 5, 6 It is, therefore, a candidate gene for the development of obesity.
Ristow et al
7 described a mutation in the PPARg gene, P115Q, in four out of 121 obese German patients, which was not found in 237 normal weight controls. Transfection of the mutant gene into ®bro-blasts resulted in their accelerated differentiation into adipocytes. Given its high frequency, these ®ndings suggest that this mutation may be an important genetic cause of obesity, at least in Germans.
Screening of the PPARg gene of patients with either type 2 diabetes mellitus (DM) or lipoatrophic diabetics for mutations 8 ± 10 has led to the identi®cation of two polymorphisms. A C?G substitution at nucleotide 39 in the exon unique to PPARg-2, which results in the replacement of proline 12 with alanine (P12A), and a C?T substitution at nucleotide 1431, which does not result in an amino acid change, histidine 453 remaining histidine.
The association of the P12A polymorphism with obesity and type 2 DM has been the subject of a number of, at times con¯icting, reports (Table 1) . Of those studies in which type 2 DM subjects were excluded, Beamer et al 11 found that the A allele of the P12A polymorphism was associated with a higher body mass index (BMI) in obese American Caucasians. On the contrary, Deeb et al 12 found that the A allele was associated with a lower BMI in middleaged and elderly Finns. Ek et al 13 found no association between carriers of the A allele and obesity amongst Danish men attending draft boards. However, after a follow-up period of approximately 24 y, A12A homozygotes who were initially obese showed a higher tendency to gain weight than P12P and P12A individuals. In contrast, A12A subjects who were initially not obese showed a reduced tendency to gain weight. In vitro studies performed by Deeb et al 12 showed that the Ala isoform had a lower af®nity for the PPAR response element (PPRE) and had reduced ability to transactivate reponsive promoters.
As the genetic in¯uence in the development of obesity increases with increasing BMI, 1 and as the most signi®cant association between the P12A polymorphism and obesity was found amongst patients with the severest obesity, 11 we decided to investigate the extent of variation in the PPARg gene in a group of morbidly obese patients (mean BMI 51) who underwent gastric restriction surgery at the Evangelisches Krankenhaus, Dinslaken, Germany. As variation in the PPARg gene has also been associated with the development of type 2 DM, such patients were excluded from our study. The incidence of the P115Q mutation and the P12A polymorphism was determined. In addition, we performed a single-strand conformational polymorphism (SSCP) screen of the entire coding region plus promoter in a sub-group of patients (n 67) to determine the extent of variation in the PPARg gene in morbidly obese patients.
Materials and methods

Study subjects
Two hundred patients undergoing gastric banding surgery at the Evangelisches Krankenhaus, Dinslaken were recruited, none of whom had type 2 DM. Blood donors (n 192) from the Blood Transfusion Service of the Universita Èts-Krankenhaus, Eppendorf, Hamburg served as normal controls. Patients gave informed consent to the study, which was approved by the local ethics committee. The characteristics of the subjects are described in Table 2 . For ethical reasons, the blood donors were anonymous and hence we were unable to obtain their BMI, however they form a suitable control group since morbidly obese patients are excluded as blood donors. Serum leptin concentrations were determined as a marker of the degree of obesity. As expected, the controls had signi®cantly lower leptin values than the obese group (P`10 -6 ).
DNA Analysis
DNA was extracted from the buffy coat obtained from 10 ml EDTA blood using standard methods. The incidence of the P115Q mutation was determined using the PCR-based restriction fragment length polymorphism assay as described by Ristow et al. 7 As a positive control, we employed the clone of the mutant constructed by Ristow et al, 7 and kindly provided by Dr Ristow. The allele frequencies of the P12A polymorphisms were determined as described by Yen et al. 8 For SSCP analysis all coding exons plus the exonaintron boundaries together with 462bp of the promoter of PPARg-2 were analysed in a total of 15 fragments using the primers and PCR conditions described by Okazawa et al. 9 PCR products were diluted 50-fold in SSCP buffer (1Âtris-borateaEDTA (TBE), 3.5 M urea), incubated for 5 min at 96 C, cooled on ice and 1ml loaded onto mini-polyacrylamide gels (Biometra). Routinely each DNA was analysed under four different gel conditions, namely 10% polyacrylamide gels with or without 10% glycerol, and electrophoresis performed at room temperature and 4 C. DNA was visualized by silver staining. SSCP variants were con®rmed by a second PCR. For sequencing of SSCP variants, the PCR fragments were puri®ed using a QIAquick PCR puri®cation kit from Qiagen. DNA sequencing was performed using ABI Prism Dye Terminator sequencing kits and analysed using an ABI Genetic Analyser 310. The sequencing primers were the same as those used for the PCR reactions.
Assay of plasma leptin
Plasma leptin concentrations were determined using the Quantikine TM human leptin immunoassay manufactured by R&D Systems Inc of Minneapolis, USA.
Results
P115Q mutation
The incidence of the P115Q mutation in the morbidly obese patients and blood donor controls was determined as described in the Materials and methods. All subjects were P115P homozygous wild-type. In neither the morbid obese patients nor the blood donors was the mutation detected. The positive control con®rmed that the assay would have detected the mutation had it been present.
P12A polymorphism
The frequency of the A allele at codon 12 in the two groups, 0.15 vs 0.16, was not statistically signi®cantly different (Table 3 ). Amongst the morbid obese patients, there were no statistically signi®cant differences in the mean BMI of any of the genotypes (Figure 1 ). There was a tendency for AA homozygotes to have a lower BMI, but this did not reach statistical signi®cance, perhaps due to small numbers. Mean serum leptin was higher in male blood donors who were AA homozygotes (12.4 AE 4.72 ngaml, n 6) then in either PP homozygotes or heterozygotes (6.6AE 0.49 ngaml, n 94 and 5.6 AE 0.57 ngaml, n 33, respectively). When corrected for age, the difference between male AA homozygotes and the rest was signi®cant (P 0.001). There was no signi®cant difference between PP homozygotes and heterozygotes. Since none of the female blood donors were AA homozygous, we cannot say whether this effect is sex speci®c. Serum leptin concentrations were measured in 71 of the morbidly obese patients from the Evangelisches Krankenhaus Dinslaken. There were no signi®cant differences between the genotypes in the leptin concentrations or in the leptinaBMI ratio, either in males or in females. Since none of the male morbid obese patients were AA homozygotes it was not possible to con®rm the effect on leptin concentrations seen in the blood donors. Leptin concentration was measured in two obese females who are AA homozygote. One had 86 ngaml leptin and a BMI of 49, the other 30 ngaml with a BMI of 46.
SSCP screening of the PPARg gene in morbidly obese patients
As published SSCP screens of the PPARg gene were performed on patients with either type 2 or lipoatrophic diabetes 8 ± 10 we thought it worthwhile to carry out an SSCP screen on a group of morbidly obese patients. DNA from 67 of the morbidly obese patients (mean BMI 51AE 7.8, 51 Fa13 M) was screened for variants in their PPARg gene as described in the Materials and methods. In addition to the reported polymorphisms, four SSCPs were obtained. One patient had a T?G transversion at 7208 in the promoter of PPARg-2. This lies outside any of the reported control sequences and is therefore unlikely to be functional. Two patients had mutations that did not result in amino acid changes. One was a T?C transition in the third base of codon 144, which thus remains asparagine, and the other CCC?CCT transi- Figure 1 Relationship between P12A genotype and BMI in morbid obese patients. Mean BMI is indicated by bars.
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The fourth patient had a CGC?TGC transition in codon 316 resulting in the replacement of an arginine with a cysteine. The remaining 103 morbid obese patients were screened for the R316C mutation, but no additional cases were found, suggesting that it is a private mutation. DNA was obtained from six sisters of the proband, one of whom also carried the mutation, but there was no correlation between carrying the mutation and BMI. It is, therefore, unlikely that this mutation is associated with obesity.
Discussion
Since we were unable to detect the PPARg P115Q mutation in the morbidly obese patients or healthy blood donors, we conclude that it is unlikely to be a common polymorphism associated with obesity in Germans. We suggest that the high incidence of the mutation reported by Ristow et al 7 is probably a founder effect due to the restricted area, the cities of Bochum and Cologne, from which the patients were recruited.
The effect of the P12A polymorphism on the BMI has been the subject of two recent reports with differing ®ndings. Beamer et al 11 determined the P12A allele frequencies in two groups of Caucasians from the Baltimore, USA region. One group, JHU-WMC (n 169), were moderately to severely obese (mean BMI 36.5, range 24.2 ± 76.8), the other, BLSA (n 516), were lean to moderately obese, (mean BMI 26.5, range 18.6 ± 43.2), neither group containing diabetics. The frequency of the A allele was 0.11 in both groups. They found that in the JLU-WMC cohort carriers of the A allele had a signi®cantly higher BMI, an effect that was more pronounced in women. There was a similar tendency in the BLSA group, but this was not signi®cant. There were too few AA homozygotes to enable them to determine any recessive effects. Deeb et al 12 investigated the frequency of the P12A polymorphism in 333 randomly chosen middleaged, non-diabetic Finns. They found, in contrast, that carriers of the A allele (frequency 0.12) had a signi®cantly lower BMI, 26.2 vs 25.0. They extended their study to include 973 elderly Finns (frequency A allele 0.15) and found that the AA homozygotes had a signi®cantly lower BMI (25.7) than heterozygotes (27.9) or PP homozygotes (27.3). Taken together these ®ndings suggest that the effect of heterozygosity for the P12A polymorphism on BMI is only manifested in subjects who are severely obese. In our study, there was no signi®cant difference in the incidence of the A allele between morbidly obese patients and normal blood donor controls. Furthermore there was no statistically signi®cant association between heterozygous carriers of the A allele and BMI. Thus we are unable to con®rm in our German population of severely obese patients (mean BMI 51) the association of P12A heterozygotes with increased BMI in severely obese subjects (mean BMI 36.5) observed by Beamer et al 11 in American Caucasians. In our study, female AA homozygotes had a lower BMI. Although this was not statistically signi®cant, perhaps due to the rarity of AA homozygotes, it is consistent with the ®ndings of Deeb et al. 12 It should be noted that the mean BMI of these homozygotes was 45, suggesting that homozygosity for the A allele may have a BMI lowering effect even in very obese subjects. Assuming that a number of factors come together to produce morbid obesity and since the patients in our study were so massively overweight, it may be that a modest effect of the P12A polymorphism on BMI is masked in this group. We cannot exclude an affect of this polymorphism on BMI in subjects with a lower degree of obesity.
In the case of male blood donors, homozygosity for the A allele was associated with signi®cantly higher serum leptin levels. That variation in the PPARg gene has an affect on plasma leptin levels was shown by Meirhaeghe et al 14 in their study of the C?T polymorphism in codon 453. In this case they found that subjects with at least one T allele had higher serum leptin. This effect was independent of BMI.
An SSCP screen of 67 morbidly obese patients did not reveal any new polymorphisms in addition to those detected during similar screens of diabetic patients. This suggests that there are no additional polymorphisms in the PPARg gene associated with morbid obesity. Only one mutation resulting in an amino acid change was found. This did not segregate with BMI within the affected family, implying that it is not responsible for the overweight. Further experiments are required in order to characterize this mutation. The results of our SSCP screen suggest that it is unlikely that mutation in the PPARg gene is common in morbid obesity.
In conclusion, we ®nd no evidence that variation in the PPARg gene plays a role in the development of morbid obesity in an ethnic German population.
